Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Predicting individual treatment response in diabetes.

Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):415-417. doi: 10.1016/S2213-8587(19)30118-4. Epub 2019 Apr 29. No abstract available.

2.

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Idzerda NMA, Stefansson BV, Pena MJ, Sjostrom DC, Wheeler DC, Heerspink HJL.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz064. doi: 10.1093/ndt/gfz064. [Epub ahead of print]

PMID:
31005993
3.

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Heerspink HJL, Coresh J, Gansevoort RT, Inker LA.

Lancet Diabetes Endocrinol. 2019 May;7(5):336-337. doi: 10.1016/S2213-8587(19)30080-4. No abstract available.

PMID:
31003622
4.

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G.

Diabetologia. 2019 Apr 17. doi: 10.1007/s00125-019-4859-4. [Epub ahead of print]

PMID:
31001673
5.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
6.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13.

PMID:
30992195
7.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
8.

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.

Vinke JSJ, Heerspink HJL, de Borst MH.

Curr Opin Nephrol Hypertens. 2019 Apr 9. doi: 10.1097/MNH.0000000000000505. [Epub ahead of print]

PMID:
30958403
9.

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney.

Heerspink HJL.

Nephrol Dial Transplant. 2019 Feb 20. pii: gfz033. doi: 10.1093/ndt/gfz033. [Epub ahead of print] No abstract available.

PMID:
30789206
10.

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium.

Kidney Int Rep. 2018 Dec 18;4(2):212-221. doi: 10.1016/j.ekir.2018.12.001. eCollection 2019 Feb. Review.

11.

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8.

PMID:
30635226
12.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
13.

Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium.

Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC).

BMJ. 2019 Jan 10;364:k5301. doi: 10.1136/bmj.k5301.

14.

New pharmacological strategies for protecting kidney function in type 2 diabetes.

Muskiet MHA, Wheeler DC, Heerspink HJL.

Lancet Diabetes Endocrinol. 2019 May;7(5):397-412. doi: 10.1016/S2213-8587(18)30263-8. Epub 2018 Dec 19. Review. Erratum in: Lancet Diabetes Endocrinol. 2019 Feb 4;:.

PMID:
30579729
15.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17.

PMID:
30559106
16.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
17.

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care.

Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L.

J Clin Med. 2018 Dec 1;7(12). pii: E499. doi: 10.3390/jcm7120499.

18.

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P.

Diabetes Obes Metab. 2019 Mar;21(3):720-725. doi: 10.1111/dom.13579. Epub 2018 Dec 11.

PMID:
30414240
19.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
20.

ACCORDION: Ensuring That We Hear the Music Clearly.

Wong MG, Heerspink HJL, Perkovic V.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. No abstract available.

PMID:
30361334

Supplemental Content

Loading ...
Support Center